Paclitaxel/Taxol / CA19-9 Cancer Research Results

PacT, Paclitaxel/Taxol: Click to Expand ⟱
Features:
Paclitaxel (brand name Taxol) is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. Administered by intravenous injection.
Derived from a natural product, Taxol (from Pacific Yew Tree).
Paclitaxel is a drug (chemotherapy; a taxane). Its dominant anticancer mechanism is microtubule stabilization, which disrupts normal mitosis and drives mitotic arrest/stress signaling that can culminate in apoptosis.


Paclitaxel – Cancer Pathway Matrix

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Microtubule stabilization → Mitotic arrest Mitotic progression ↓; spindle dynamics impaired; cell division blocked Proliferating normal cells affected R, G Core cytotoxic mechanism Binds β-tubulin and stabilizes microtubules, preventing normal depolymerization required for mitosis.
2 Spindle assembly checkpoint activation Prolonged mitotic arrest → mitotic catastrophe or apoptosis Checkpoint stress in dividing tissues R, G Mitotic stress execution Cell fate depends on whether arrest resolves via apoptosis or mitotic slippage.
3 Intrinsic apoptosis (mitochondrial pathway) Caspase activation ↑; BAX/mitochondrial signaling engaged (context) Limited unless stressed G Cell death execution Often downstream of prolonged mitotic stress and mitochondrial perturbation.
4 ROS generation (secondary) ROS ↑ (context-dependent); oxidative stress amplification Oxidative stress possible in sensitive tissues R, G Stress amplifier ROS rise appears secondary to mitotic and mitochondrial dysfunction; may enhance apoptosis.
5 Nrf2 antioxidant response (adaptive) Nrf2 ↑ in some tumors; antioxidant buffering ↑; resistance potential Protective antioxidant signaling G Adaptive resistance axis Not a direct paclitaxel target; elevated Nrf2 may reduce drug sensitivity.
6 Drug resistance mechanisms P-glycoprotein (MDR1) ↑; β-tubulin alterations; survival rewiring — G Treatment failure driver Efflux pumps and tubulin adaptations are major clinical resistance mechanisms.
7 Myelosuppression — Neutropenia risk ↑ G Dose-limiting toxicity Bone marrow suppression is a primary clinical constraint.
8 Peripheral neuropathy — Sensory neuropathy risk ↑ G Dose-limiting toxicity Likely related to microtubule disruption in axonal transport.

Time-Scale Flag (TSF):
P = 0–30 min (drug binding begins)
R = 30 min–3 hr (mitotic stress signaling, ROS changes)
G = >3 hr (apoptosis, resistance adaptation, tissue toxicities)



CA19-9, CA 19-9: Click to Expand ⟱
Source:
Type: biomarker
CA 19-9 and Cancer — Tumor Burden Marker, Treatment Monitoring Tool, and Its Limits
CA 19-9 (also known as sialyl-Lewis A) is a glycan epitope expressed on mucins and other glycoproteins. It is not a gene and not a cancer-specific molecule by design.

Typically UPREGULATED in circulation in certain cancers due to increased production and/or impaired biliary clearance.
Elevation reflects tumor burden and ductal involvement, not oncogenic signaling.
Where CA 19-9 Is Clinically Relevant
Highest utility:
-Pancreatic ductal adenocarcinoma (PDAC)
-Cholangiocarcinoma
-Gallbladder cancer

Secondary/limited utility:
-Gastric and colorectal cancers (subset; nonspecific)

Appropriate uses
-Baseline assessment at diagnosis (prognostic)
-Monitoring response to therapy
-Detecting recurrence after treatment
-Trend analysis over time (most important)

CA 19-9 can be elevated without cancer, especially with:
-Biliary obstruction or cholestasis
-Cholangitis or pancreatitis
-Liver disease

The Lewis Antigen Issue (Often Missed)
~5–10% of people are Lewis antigen–negative (Leᵃ⁻ᵇ⁻) and cannot synthesize CA 19-9.
Implications:
-CA 19-9 may be falsely low or undetectable despite advanced cancer
-A “normal” CA 19-9 does not exclude disease in these patients

Higher baseline CA 19-9 → worse prognosis (on average)


Scientific Papers found: Click to Expand⟱
7505- HCQ,  GEM,  PacT,    A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients
- Trial, PC, NA
eff↑, TumAuto↓, Imm↑, CA19-9↓, OS↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Imm↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

CA19-9↓, 1,  

Functional Outcomes(tgid=23) ⓘ

OS↑, 1,  
Total Targets: 5

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: CA19-9, CA 19-9
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:182  Target#:1412  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page